LY-3381916

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLY-3381916
Drug Alias NameLY-3381916
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A